The mutations identified in both studies cluster in the ESR1 region encoding the ligand-binding domain (LBD) of ERα, at amino acids 534-538. Toy et al. 4 also identified mutations affecting Ser463, and Li et al. 2 found an additional alteration at Glu380. Previous studies have shown that mutations affecting the LBD of ERα result in ligand-independent activity 7-11 , and both Toy et al. 4 and Robinson et al. 3 showed that the ERα LBD alterations they identified cause constitutive, estrogen-independent receptor activity. 
ESR1 mutations and resistance
The mutations identified in both studies cluster in the ESR1 region encoding the ligand-binding domain (LBD) of ERα, at amino acids 534-538. Toy et al. 4 also identified mutations affecting Ser463, and Li et al. 2 found an additional alteration at Glu380. Previous studies have shown that mutations affecting the LBD of ERα result in ligand-independent activity [7] [8] [9] [10] [11] , and both Toy et al. 4 and Robinson et al. 3 showed that the ERα LBD alterations they identified cause constitutive, estrogen-independent receptor activity. Toy et al. 4 additionally showed that mutant ERα proteins induce expression of novel target genes and performed elegant molecular modeling of the mutant receptors, showing that the identified changes lead to the stabilization of an agonist conformation, especially in the coactivator-recruiting region in helix 12, through the formation of hydrogen bonds between Ser537 (and Gly538) and Asp351. Previous studies showed that LBD mutants of ERα demonstrate increased interaction with the coactivator AIB1 and increased phosphorylation frequency of 22% (20/91 cases) for ESR1 mutations in advanced breast cancer. Both groups sequenced primary tumors obtained before therapy for a subset of cases with ESR1 mutation and showed that ESR1 mutations were not present in the treatment-naive cancers. Robinson et al. 3 did not find ESR1 mutations in 80 breast cancers that lacked ER and progesterone receptor expression. Toy et al. 4 also reported an analysis of 183 pretreatment tumor biopsies from BOLERO-2 trial participants in which they identified ESR1 mutations in only 3% of cases. Similarly, a previous study of 46 pretreatment ER + tumor biopsies did not identify any ESR1 mutations 6 . Most of these studies were performed using deep sequencing approaches, which should have allowed the identification of de novo mutations, even if they were present only in minor cell populations in heterogeneous breast cancers. Thus, ESR1 mutations are rare in newly diagnosed, untreated breast cancers but appear to be frequently acquired during progression to hormone resistance, especially in the context of estrogen deprivation therapy.
For nearly four decades, blockade of estrogen receptor α (ERα) action has been a successful treatment strategy for women with breast cancers expressing ER. Unfortunately, de novo or acquired resistance to endocrine therapy is common. Mutations affecting ER have been proposed as a possible mechanism for this resistance, but ESR1 mutations were found to be infrequent in primary breast cancer. Indeed, in sequencing 390 primary cancers positive for ER expression (ER + ), The Cancer Genome Atlas Research Network did not identify any ESR1 mutations 1 . Given the relevance of ER for the development and progression of breast cancer, identifying the mechanism of resistance to endocrine therapy is an important problem to solve. A clue to the underlying mechanism surfaced recently in a report by Matthew Ellis and colleagues 2 that described the identification of ESR1 mutations in xenografts derived from primary or metastatic breast cancers that were resistant to aggressive treatment. Now, two independent studies in this issue by Arul Chinnaiyan and colleagues 3 and Sarat Chandarlapaty and colleagues 4 show that activating ESR1 mutations are relatively frequent events in advanced ER + hormone-resistant breast cancer, particularly in metastatic lesions from women who took estrogenlowering drugs such as aromatase inhibitors.
ESR1 mutations in metastatic tumors
Robinson et al. 3 and Toy et al. 4 identified somatic ESR1 mutations in 6 of 11 (55%) and 9 of 36 (25%) ER + metastatic breast tumors, respectively. Further, Toy et al. 4 identified somatic ESR1 mutations in 5 of 44 (11%) ER + metastatic breast cancers obtained from participants in the BOLERO-2 clinical trial whose disease had progressed during treatment with aromatase inhibitors 5 . Combining the results from these two studies leads to an estimated
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Two new studies report the identification of activating ESR1 gene mutations in aromatase inhibitor-resistant metastatic breast cancers. This insight into therapeutic resistance suggests new approaches that may be useful in the management of endocrine-resistant breast cancer. n e w s a n d v i e w s of Ser118, known to be important for both the ligand-dependent and ligand-independent activity of ER [12] [13] [14] . Taken together, these studies show that mutations in ESR1 affecting the LBD result in receptors that are highly active in the absence of ligand and could cause resistance to therapy with aromatase inhibitors.
Do ESR1 mutations matter?
These studies raise questions about the potential clinical implications of ESR1 mutations in advanced, treatment-resistant ER + disease. Toy et al. 4 reported no obvious difference in response to aromatase inhibitors for tumors with wild-type or mutant ERα in individuals enrolled in the BOLERO-2 clinical trial, but few samples were studied, and all were derived from patients whose tumors had already progressed on therapy with aromatase inhibitors. Future studies will be required to address whether ESR1 mutations associate with altered clinical outcome. Another critical question is whether detection of these mutations can guide selection of therapy. Both Toy et al. 4 and Robinson et al. 3 showed that mutant ERα protein can still bind antiestrogens such as tamoxifen and fulvestrant, although higher doses of these drugs are required to inhibit mutant ERα. Thus, it is possible that the doses needed to achieve potent ERα inhibition in ESR1-mutant tumors might exceed the steady-state intratumoral levels that are routinely achieved in the clinic. This raises the possibility that altered dosing or the development of more potent and/or selective ER antagonists might inhibit residual ER activity and thus overcome resistance. Toy et al. 4 suggest that the mutant ERα proteins may have a different conformation, which provides the exciting opportunity to screen for drugs specific for mutant ERα proteins, as has been done for BCR-ABL 15 . If replicated, these results are likely to stimulate the development of tests designed to monitor patients on therapy with aromatase inhibitors for the development of ESR1 mutations, perhaps through sequencing of circulating free DNA, so that corresponding changes in therapy can be made. In summary, the studies by the Chinnaiyan and Chandarlapaty groups show that ESR1 mutations are rare in primary breast cancer, seldom arise under the pressure of treatment with selective ER modulators, such as tamoxifen, and are most likely to have a functional role in acquired resistance to estrogen deprivation, such as that occurring during therapy with aromatase inhibitors (Fig. 1) . The finding that the identified mutations cluster in the ESR1 region encoding the LBD of ERα, resulting in a constitutively active receptor with a different conformation, is both mechanistically pleasing and potentially tractable for the development of new targeted strategies.
